On March 28, 2019 Shuwen Biotech reported that Tasly Pharmaceutical Group has tapped Shuwen Biotech for clinical services and proprietary diagnostics for its oncology drug candidates (Press release, Shuwen Biotech, MAR 28, 2019, View Source [SID1234554004]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With the shifting economic macro-environment globally, the need for cost-saving, innovative and personalized diagnostics is more than ever before. We at Shuwen aim to add value not only to committed innovators in the pharmaceutical space like Tasly, but ultimately to all patients in need of healthcare treatments," commented Jay Z. Zhang, Chairman and CEO of Shuwen Biotech.

The two companies plan to use Shuwen’s established companion diagnostic development team and CAP-accredited reference labs to drive clinical outcomes and ultimately deliver the most innovative and life-saving solutions to patients and healthcare professionals globally.